EFFECT OF ANTIBODIES TO ESTRADIOL AND PROGESTERONE ON THE CONCENTRATIONS THESE HORMONES IN SERUM OF HEALTHY WOMEN AND BREAST CANCER PATIENTS

Cover Page

Cite item

Full Text

Abstract

Antibodies to benzo[a]pyrene, estradiol and progesterone (IgA-Bp, IgA-Es and IgA-Pg) in the serum of 222 postmenopausal healthy women (HW) and 266 breast cancer patents (BCP) were studied. Positive linear correlations IgA-Es and IgA-Pg with IgA-Bp were found in all the groups (rs = 0,53–0,8, p < 0,0001). Frequency of high both IgA-Es and IgA-Pg levels (33,3%) was more high at ER+PR+ BCP than at HW (22,1%) and ER–PR– (22,7%) and ER+PR– (21,4%) BCP (OR = 2,2). Frequency of high Es concentration (>0,15 nmol/l) and Pg concentration (>1,4 nmol/l) in the serum of HW were revealed when both IgA-Es and IgA-Pg levels were high (67,7 and 59,5%) instead of these levels were low (25,8 and 21,6% correspondingly). Frequency of high Pg concentration (>0,75 nmol/l) were more high when both IgA-Es and IgA-Pg levels were high (49,3%) instead of these levels were low (26,1%) in the serum of ER+PR+ BCP. So IgA-Es together with IgA-Pg stimulated proliferation of normal ER+PR+ mammary cells (promotion of carcinogenesis), but inhibited proliferation of ER+PR+ malignant mammary cells (progression of carcinogenesis). It was supposed that induction IgA-Bp by anti-carcinogens vaccines for active cancer immunoprevention could stimulate antibodies formation against other endogenous steroids, mineralocorticoids and glucocorticoids, with the following negative consequences. There is the reason to use IgA-Es and IgA-Pg immunoassay for ER+PR+ breast cancer prediction and following prevention by selective modulators of ER (tamoxifen and others).

About the authors

A. N. Glushkov

The Federal Research Center of Coal and Coal Chemistry of Siberian Branch of the Russian Academy of Sciences, Institute of Human Ecology; Kemerovo State University

Author for correspondence.
Email: ihe@list.ru

MD, Professor, Director of Institute of Human Ecology of FRC CCC SB RAS

650065 Kemerovo, avenue Leningradsky, 10

Russian Federation

E. G. Polenok

The Federal Research Center of Coal and Coal Chemistry of Siberian Branch of the Russian Academy of Sciences, Institute of Human Ecology

Email: fake@neicon.ru

PhD (Candidate of Pharmacy), Chief of Immunochemistry Laboratory

Kemerovo

Russian Federation

M. V. Kostyanko

Kemerovo State University

Email: fake@neicon.ru

Leading Engineer of the Department of Organic Chemistry of Faculty of Chemistry

Kemerovo

Russian Federation

A. V. Antonov

Regional Clinical Oncology Hospital, Kemerovo

Email: fake@neicon.ru

Chief of Mammology Department 

Kemerovo

Russian Federation

N. E. Verzhbitskaya

Pathologoanatomic Bureaus, Kemerovo

Email: fake@neicon.ru

PhD (Candidate of Medicine), Chief of Patholoanatomical Department 

Kemerovo

 

Russian Federation

I. A. Vafin

Regional Center of Blood, Kemerovo

Email: fake@neicon.ru

Main Physician

Kemerovo

Russian Federation

S. E. Ragozhina

Regional Center of Blood, Kemerovo

Email: fake@neicon.ru

Assistant of Main Physician on Medicine 

Kemerovo

Russian Federation

References

  1. De Buck S. S., Augustijns P., Muller C. P. Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J. Pharmacol. Experim. Therap. 2005, 313(2), 640–646.
  2. De Buck S. S., Schellenberger M. T., Ensch C., Muller C. P. Effects of antibodies induced by a conjugate vaccine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone absorptive transport, metabolism, and proliferation of human lung cells. Int. J. Cancer 2010, 1, 127(3), 513–520.
  3. Moolten F.L., Schreiber B., Rizzone A. Protection of mice against 7.12 – dimethilbenz(a)anthracene – induced skin tumors by immunization with fluorinated analog of carcinogen. Carcer Res. 1981, 41, 452–459.
  4. Silbart L.K., Keren D. F. Reduction of intestinal carcinogen absorption by carcinogen-specific immunity. Science 1989, 243, 1462–1464.
  5. Silbart L.K., Mc Allen F., Rasmussen H. V. Selective induction of mucosal immune responses to 2-acetylaminofluorene. Anticancer Res. 1996, 16, 651–660.
  6. Moolten F.L., Schreiber B., Rizzone A. Protection of mice against 7.12 – dimethilbenz(a)anthracene – induced skin tumors by immunization with fluorinated analog of carcinogen. Carcer Res. 1981, 41, 452–459.
  7. Peck R.M., Peck E. B. Inhibition of chemically induced neoplasia by immunization with an antigenic carcinogen-protein conjugate. Cancer Res. 1971, 31, 1550–1554.
  8. Cernohorska H., Klimesova S., Lepsa L., Jinoch P., Milcova A., Schmuczerova J., Topinca J., Labaj J. Influence of immunization with non-genotoxic PAH-KLH conjugates on the resistance of organisms exposed to benzo[a]pyrene. Mut. Res. 2012, 742, 2–10.
  9. Galati R., Crebelli R., Zijno A., Conti L., Falasca G., Verdina A. The effect of humoral immunity against adducted benzo[a]pyrene on DNA damage elicited by acute carcinogen exposure in Swiss mice. In Vivo 2000, 14(6), 747–751.
  10. Tompa A., Curtis G., Ryan W., Kusrynski C., Langenbach R. Benzo[a]pyrene antibody inhibition of benzo[a]pyrene-induced mutagenesis. Cancer Lett. 1979, 7, 163–169.
  11. Silbart L.K., Rasmussen H. V., Oliver A. R. Immunoprophylactic intervention in chemical toxicity and carcinogenicity. Vet. Hum. Toxicol. 1997, 39(1), 37–43.
  12. De Buck S. S., Muller C. P. Immunopropylactic approaches against chemical carcinogenesis. Vaccine 2005, 23(17–18), 2403–2406.
  13. Худолей В. В. Канцерогены: характеристики, закономерности, механизмы действия. НИИ Химии СПбГУ, Санкт-Петербург 1990, 419 c.
  14. Sundaram K., Tsong Y. Y., Hood W., Brinson A. Effect of immunization with estrone-protein conjugate in rhesus monkeys. Endocrinology 1973, 93(4), 843–847.
  15. Schwartz U., Dyrenfurth I., Khalaf S., Vande Wiele R. L., Ferin M. A comparison of the effects of active immunization of female rhesus monkeys to estradiol-17 or progesterone-20-protein conjugates. J. Steroid Biochem. 1975, 6(3–4), 541–545.
  16. Hillier S.G., Groom G. V., Boyns A. R., Cameron E. H. Effects of active immunisation against steroids upon circulating hormone concentrations. J. Steroid Biochem. 1975, 6(3–4), 529–535.
  17. Rawlings N.C., Kennedy S. W., Henricks D. M. The active immunization of the cyclic ewe against an estrone protein conjugate. Theriogenology 1979, 12(3), 139–151.
  18. Caldwell B.V., Tillson S. A., Esber H., Thorneycroft I. H. Survival of tumors after immunization against estrogens. Nature 1971, 231(14), 118–119.
  19. Глушков А.Н., Поленок Е. Г., Костянко М. В., Титов В. А., Вафин И. А., Рагожина С. Е. Взаимное влияние антител к бензо[a]пирену, эстрадиолу и прогестерону на риски возникновения рака легкого. Российский иммунологический журнал 2015, 9(18), 3, 343–349.
  20. Glushkov A.N., Polenok E. G., Ustinov V. A. Immunomodulation of human carcinogenesis by the serum antibodies to environmental carcinogens and endogenous steroids. Open Immunol. Journal 2016, 6(3), 67–72.
  21. Глушков А.Н., Поленок Е. Г., Магарилл Ю. А., Аносова Т. П., Антонов А. В., Вержбицкая Н. Е. Антитела к бензо[а]пирену, эстрадиолу и прогестерону у больных раком молочной железы в постменопаузе. Сибирский онкологический журнал 2016 (в печати).
  22. Глушков А.Н., Поленок Е. Г., Аносова Т. П., Савченко Я. А., Баканова М. Л., Минина В. И., Мун С. А., Ларин С. А., Костянко М. В. Сывороточные антитела к бензо[a]пирену и хромосомные аберрации в лимфоцитах периферической крови у рабочих углеперерабатывающего предприятия. Российский иммунологический журнал 2011, 5(14), 1, 39–44.
  23. Hajian-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. Caspian J. Intern. Med. 2013, 4(2), 627–635.
  24. Newman M.J., Light B. A., Weston A., Tollurud D., Clark J. L., Mann D. L., Blackmon J. P., Harris C. C. Detection and characterization of human serum antibodies to polycyclic aromatic hydrocarbon diol-epoxide DNA adducts. J. Clin. Invest. 1988, 82(1), 145–153.
  25. Chlebowski R.T., Anderson G. L., Gass M., Lane D. S., Aragaki A. K., Kuller L. H., Manson J. E., Stefanick M. L., Ockene J., Sarto G. E., Johnson K. C., Wactawski-Wende J., Ravdin P. M., Schenken R., Hendrix S. L., Rajkovic A., Rohan T. E., Yasmeen S., Prentice R. L.; WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304(15), 1684–1692.
  26. Mohammed H., Russell I. A., Stark R., Rueda O. M., Hickey T. E., Tarulli G. A., Serandour A. A., Birrell S. N., Bruna A., Saadi A., Menon S., Hadfield J., Pugh M., Raj G. V., Brown G. D., D’Santos C., Robinson J. L., Silva G., Launchbury R., Perou C. M., Stingl J., Caldas C., Tilley W. D., Carroll J. S. Progesterone receptor modulates ERα action in breast cancer. Nature 2015, 523(7560), 313–317.
  27. Glushkov A., Polenok E., Kostyanko M., Antonov A., Verzhbitskaya N., Vafin I., Ragozhina S. Postmenopausal breast cancer risk in relation to antibodies specific to benzo[a]pyrene, estradiol and progesterone. Iran J. Cancer Prev. 2016, 9(2), e4212.
  28. Stabile L.P., Dacic S., Land S. R., Lenzner D. E., Dhir R., Acquafondata M., Landreneau R. J., Grandis J. R., Siegfried J. M. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin. Cancer Res. 2011, 17(1), 154–164.
  29. Charles G.D., Bartels M. J., Zacharewski T. R., Gollapudi B. B., Freshour N. L., Carney E. W. Activity of benzo[a]pyrene and its hydroxylated metabolites in an estrogen receptor-alpha reporter gene assay. Toxicol. Sci. 2000, 55(2), 320–326.
  30. Глушков А.Н., Поленок Е. Г., Костянко М. В., Антонов А. В., Вержбицкая Н. Е., Вафин И. А., Рагожина С. Е. Ассоциации сывороточных антител к эстрадиолу с рецепторами эстрогенов в опухоли у больных раком молочной железы. Российский иммунологический журнал 2016, 10(19), 2, 166–173.
  31. Glushkov A.N., Klimov I. A., Anosova T. P., Schukina M. L. Antibodies to polycyclic aromatic hydrocarbons in sera of patients with malignant mammary tumors. Experim. Oncol. 1996, 18(3), 284–286.
  32. Ustinov V.A., Matveeva V. A., Kostyanko M. V., Glushkov A. N. Antibodies against benzo[a]pyrene in immunized mouse and lung cancer patients. Experim. Oncol. 2013, 35(3), 207–210.
  33. Глушков А. Н. Клиническая иммунохимия канцерогенеза: новые задачи и перспективы. Российский иммунологический журнал 2013, 7(16), 1, 27–34.
  34. Ustinov V.A., Studennikov A. E., Vavilov V. A., Tyumentseva M. A., Morozova V. V., Tikunova N. V., Glushkov A. N. Generation and characterization of human single-chain antibodies against polycyclic aromatic hydrocarbons. Immunol. Invest. 2015, 44(6), 536–552.
  35. Martino S., Costantino J., McNabb M., Mershon J., Bryant K., Powles T., Secrest R. J. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 2004, 9(2), 116–125.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Glushkov A.N., Polenok E.G., Kostyanko M.V., Antonov A.V., Verzhbitskaya N.E., Vafin I.A., Ragozhina S.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies